**6. References**


Amyloid Beta Binding with D-Peptides 69

Kumar-Singh S, Julliams A, Nuydens R, Ceuterick C, Labeur C, Serneels S, Vennekens K,

Lazarov O, Lee M, Peterson DA, Sisodia SS, Evidence that synaptically released beta-

Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S,

Lee VM. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging. 2002

Masters CL, Beyreuther K, Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 2006;29:2823-39. McGowan E, Eriksen J, Hutton M, A decade of modeling Alzheimer's disease in transgenic

Monaco S, Zanusso G, Mazzucco S, Rizzuto N, Cerebral amyloidoses: molecular pathways

Morimatsu M, Hirai S, Muramatsu A, Yoshikawa M. Senile degenerative brain lesions and

Nagele RG, D'Andrea MR, Anderson WJ, Wang HY, Intracellular accumulation of beta-

Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY, Astrocytes accumulate A

Paresce DM, Ghosh RN, Maxfield FR, Microglial cells internalize aggregates of the

Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi

Rogers J, Lue LF, Microglial chemotaxis, activation, and phagocytosis of amyloid beta-

Rogers J, Strohmeyer R, Kovelowski CJ, Li R, Microglia and inflammatory mechanisms in

Satpute-Krishnan P, DeGiorgis JA, Conley MP, Jang M, Bearer EL, A peptide zipcode

Selkoe DJ, Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001 81:741-66. Sheng JG, Price DL, Koliatsos VE, Disruption of corticocortical connections ameliorates

the clearance of amyloid beta peptide. Glia. 2002 40:260-269.

amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine

beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains.

Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996

F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M, Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and

peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001 39:333-

sufficient for anterograde transport within amyloid precursor protein. Proc Natl

amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J

and therapeutic challenges. Curr Med Chem. 2006 13:1903-1913.

receptor in Alzheimer's disease. Neuroscience. 2002 110:199-211.

derivative. J Neuropathol Exp Neurol., 2002 61:797-805.

neurotoxicity. Neurobiol Dis., 2002;11:330-40.

mice. J Neurosci., 2002;22:9785-93.

mice. Trends Genet. 2006 22:281-9.

Brain Res. 2003 971:197-209.

17:553-565.

340.

dementia. J Am Geriatr Soc. 1975 23:390-406.

robust pathology. EMBO Rep. 2006 7:940-946.

Acad Sci U S A. 2006 103:16532-7.

Neurosci. 2002 22:9794-9.

2005 25:2386-2395.

23:1039-1042.

multiphoton microscopy and methoxy-X04, a systemically administered Congo red

Van Osta P, Geerts H, De Strooper B, Van Broeckhoven C. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged

amyloid accumulates as extracellular deposits in the hippocampus of transgenic

Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS, Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci.


Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada C-M,

Braak H, Braak E, Neuropathological stageing of Alzheimer-related changes. Acta

Braak H, Braak E, Evolution of neuronal changes in the course of Alzheimer's disease. J.

D'Andrea MR, Nagele RG, Wang HY, Lee DH. Consistent immunohistochemical detection

Demeester N, Mertens C, Caster H, Goethals M, Vandekerckhove J, Rosseneu M, Labeur C.

Dickson TC, Vickers JC, The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 2001 105:99-107. Duff K, Normal and abnormal tau neurobiology. Alzheimer Dis Assoc Disord., 2006 20:202-

Duff K, Suleman F, Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic. 2004 3:47-59. Funke SA, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, Sehl T, Batra-

Glenner GG. The bases of the staining of amyloid fibers: their physico-chemical nature and

Guntern R, Bouras C, Hof PR, Vallet PG. An improved thioflavine S method for staining

Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US

Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL,

Inouye H, Kirschner DA. Alzheimer's beta-amyloid: insights into fibril formation and structure from Congo red binding. Subcell Biochem. 2005 38:203-224. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR, Co-

Kadish I, Van Groen T, Low levels of estrogen significantly diminish axonal sprouting after entorhinal cortex lesions in the mouse. J Neurosci., 2002;22:4095-102. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt

Neuron, 1996 17:1005-1013.

205.

13:1-37.

48:8-10.

1122.

1996;271:22908-14.

Biomol Eng., 2001;17:157-65.

Neuropathol. 1991 82:239-259.

Neuroscience 2010 1:639-648.

Neural. Transm., 1998 53:127-40.

entorhinal cortex. Neurosci Lett., 2002 333:163-166.

peptides. Eur J Neurosci., 2001 13:2015-2024 .

Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger, M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS, Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo.

of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease

Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch N-terminally truncated amyloid beta

Safferling R, Moriscot C, Schoehn G, Horn AHC, Muller-Schiffmann A, Korth C, Sticht H, Willbold D. Oral treatment with the D-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's disease transgenic mice. ACS Chemical

the mechanism of their dye-substrate interaction. Prog Histochem Cytochem. 1981

neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia. 1992

population: prevalence estimates using the 2000 census. Arch Neurol. 2003 60:1119-

Beyreuther K, Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem.,

expression of multiple transgenes in mouse CNS: a comparison of strategies.

DP, Wang Y, Hyman BT, Imaging Abeta plaques in living transgenic mice with

multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol., 2002 61:797-805.


**Part 2** 

**Sexual Disorders** 


**Part 2** 

**Sexual Disorders** 

70 Neuroimaging for Clinicians – Combining Research and Practice

Stalder M, Deller T, Staufenbiel M, Jucker M, 3D-Reconstruction of microglia and amyloid in

Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red:

Tsubuki S, Takaki Y, Saido TC, Dutch, Flemish, Italian, and Arctic mutations of APP and

Uchihara T, Nakamura A, Yamazaki M, Mori O. Tau-positive neurons in corticobasal

Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis NK, Bouras C. A comparative

van Groen T, Kiliaan AJ, Kadish I, Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis. 2006 23:653-62. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, Willbold D. Reduction of

van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D. In vitro and in vivo staining

Van Nostrand WE, Melchor JP, Romanov G, Zeigler K, Davis J, Pathogenic effects of

Van Regenmortel MH, Muller S, D-peptides as immunogens and diagnostic reagents. Curr

Vetrivel KS, Thinakaran G, Amyloidogenic processing of beta-amyloid precursor protein in

Wang J, Tanila H, Puolivali J, Kadish I, van Groen T, Gender differences in the amount and

Watson DJ, Selkoe DJ, Teplow DB, Effects of the amyloid precursor protein Glu693-->Gln

Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D,

Wiesehan K, Stöhr J, Nagel-Steger L, van Groen T, Riesner D, Willbold D. Inhibition of

transgenic AD mouse models. ChemMedChem. 2009 4:276-282.

intracellular compartments. Neurology. 2006 66(Suppl 1):S69-73.

impregnations. Acta Neuropathol. 2000 100:385-389.

pathway lesions. Neuroscience. 2003 119:1185-97.

2001 22:427-434.

361:1957-1958.

2008 3:1848-1852.

N Y Acad Sci. 2002 977:258-265.

Opin Biotechnol. 1998 9:377-382.

Dis. 2003 14:318-327.

J. 1999 340:703-709.

2003 4:811-5.

2008 21:241-246.

Cytochem. 2000 48:1223-1232.

APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging.

a novel histochemical stain for Alzheimer's disease pathology. J Histochem

resistance of Abeta to physiologically relevant proteolytic degradation. Lancet. 2003

degeneration and Alzheimer's disease--distinction by thiazin red and silver

study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol. 1992 83:170-178. van Groen T, Liu L, Ikonen S, Kadish I, Diffuse amyloid deposition, but not plaque number,

is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by

Alzheimer's disease amyloid plaque load in transgenic mice by D3, A Denantiomeric peptide identified by mirror image phage display. ChemMedChem.

characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in

cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann

deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol

'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem

Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display Chembiochem. 2003 4:748-53. Wiesehan K, Willbold D, Mirror-image phage display: aiming at the mirror. Chembiochem.

cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel.

**5** 

 *Spain* 

Juan Antonio Becerra-García

*Department of Psychology, University of Jaén,* 

**Magnetic Resonance Techniques in Study of** 

The sexual aggression of children is a major public health and criminological issue and a paedophilic crime causes considerable public concern. Paraphilias are deviant sexual behaviors that have common clinical features: sexual fantasies leading to sexual urges and, ultimately, to the deviant sexual behavior. In these group of disorders is include the paedophilia (American Psychiatric Association [APA], 2000). Paedophilia is defined as a psychiatric disorder characterized by intense sexually arousing urges and behaviours focused on the sexual activity with a prepubescent child (APA, 2000; Fagan et al., 2002). The ICD-10 defines paedophilia as a sexual preference for children, boys or girls or both, usually

The Diagnostic and Statistical Manual of Mental Disorders, define a paedophile as an individual who fantasizes about, is sexually aroused by, or experiences sexual urges toward prepubescent children (generally <13 years) for a period of at least 6 months. Paedophiles are either severely distressed by these sexual urges, experience interpersonal difficulties because of them, or act on them (diagnostic criteria, according to the DSM-IV-TR, are shown in Table 1), usually come to medical or legal attention by committing an act against a child because most do not find their sexual fantasies distressing or ego-dystonic enough to voluntarily seek treatment. The clinical diagnosis of paedophilia is based on a specific act, it usually is not solely the result of intoxication or caused by another state or condition (APA,

Paedophiles are subdivided into several classifications. One of the first classifications divided to the paedophiles in two groups, group "exclusively" attracted to children (exclusive paedophile) or attracted to adults as well as children (nonexclusive paedophile group) (APA, 2000). Other categorization of paedophiles is based in if they are attracted to only male children (homosexual paedophilia), female children (heterosexual paedophilia),

The course of paedophilia is usually long term and has yet no cure. The onset of paedophilia usually occurs during adolescence. Occasional paedophiles begin their activities during middle age but this late onset is uncommon. The frequency of behavior associated with paedophilia varies with psychosocial stress . As the paedophile's stress levels increase, the frequency of his or her acting out generally rises also. Various treatments are available. The medical treatments (medications anti-androgens, luteinizing hormone-releasing hormone agonists, female hormones, antidepressant ) and psychological treatments (aversive

of prepubertal or early pubertal age (World Health Organization [WHO], 2010).

or children from both sexes (bisexual paedophilia).

**1. Introduction** 

2000).

**Sexual Stimuli Processing in Paedophilia** 
